Drugs / oxygen-ozone
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT07171840 | May 2021 → Jul 2022 | osteoarthritis, hand | Humanitas Clinical and Research Center | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01709058 | Aug 2012 → Dec 2014 | — | Istituto Nazionale di Ricovero e Cura per Anziani | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07504432 Background | Mar → Nov 2024 | — | University of Catanzaro | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | oxygen-ozone | “Intramuscular paravertebral oxygen-ozone (O₂O₃) therapy was administered using a gas mixture at a concentration of 10 μg/mL, with a total volume of 10 mL per session.” NCT07504432 ↗ |
| Known as | O₂O₃ | “Intramuscular paravertebral oxygen-ozone (O₂O₃) therapy was administered using a gas mixture at a concentration of 10 μg/mL, with a total volume of 10 mL per session.” NCT07504432 ↗ |
| Route | Intramuscular | “Intramuscular/paravertebral injections of Oxygen-Ozone” NCT01709058 ↗ |